This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ZELTIQ(R) Aesthetics Appoints Mark J. Foley As President And Chief Executive Officer

PLEASANTON, Calif., Aug. 24, 2012 (GLOBE NEWSWIRE) -- ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ) a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that it has appointed Mark J. Foley as President and Chief Executive Officer, effective immediately. Mr. Foley previously served as Interim President and CEO since April 2012 and as a member of the Board of Directors since 2009. 

Bryan Roberts, Ph.D., Chairman of ZELTIQ's Nominating and Governance Committee and a Partner at Venrock, commented, "We are very pleased that Mark will be serving as President and CEO on a permanent basis. With 25 years of experience in the medical device industry, and an in-depth understanding of ZELTIQ's business, Mark was the ideal candidate for the CEO role. Under Mark's leadership as interim CEO, ZELTIQ delivered a very strong Q2 performance and made significant progress in strengthening and streamlining the organization. We have great confidence that he will be successful in executing ZELTIQ's growth strategy and building on our position as the market leader in non-surgical fat reduction."

Prior to Mr. Foley's appointment as Interim President and CEO, he served on the Company's Board of Directors since 2009 and held the position of Executive Chairman until May 2010. Mr. Foley has 25 years of medical device operating, investment, board, and CEO experience. Mr. Foley currently serves as a Managing Director for RWI Ventures, Executive Chairman for Onpharma, Senior Advisor to TauTona Group, and as a Director for Sonitus Medical and Voyage Medical.  Mr. Foley's prior experience includes a variety of senior operating roles with large cap companies and venture-backed start-up's such as US Surgical Corporation, Guidant, DVI (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where he was the founder and CEO. Mr. Foley received his B.A. from the University of Notre Dame.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs